A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
NCT07158242
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Moderately to Severely Active Ulcerative Colitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Children's Hospital Colorado · Aurora, CO
Connecticut · 1
- Connecticut Children's Medical Center · Hartford, CT
Florida · 1
- University of South Florida · Tampa, FL
Georgia · 1
- Children's Healthcare of Atlanta · Atlanta, GA
Missouri · 1
- Washington University · St Louis, MO
New York · 2
- Northwell Health · Lake Success, NY
- NYU Langone Health · New York, NY
Pennsylvania · 1
- UPMC Childen?s Hospital of Pittsburgh · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.